XXII

Price Data

22nd Century Group Inc (Ticker: XXII) is a pioneering biopharmaceutical and agricultural firm focused on tobacco harm reduction via advanced genetic engineering. The company is committed to developing low-nicotine tobacco products to mitigate nicotine addiction, thereby promoting better public health outcomes. In addition to its core focus, 22nd Century is strategically expanding into the rapidly evolving hemp and cannabis markets, positioning itself favorably within the burgeoning legal cannabis industry. With a strong emphasis on scientific research and regulatory compliance, 22nd Century emerges as an attractive investment opportunity for institutional investors seeking to engage in transformative and socially responsible sectors.